Sonoma Pharmaceuticals (STU:O8Z) Interest Expense : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sonoma Pharmaceuticals's interest expense for the three months ended in Sep. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sonoma Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was € -0.77 Mil. Sonoma Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was € 0.00 Mil. GuruFocus does not calculate Sonoma Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sonoma Pharmaceuticals Interest Expense Historical Data

The historical data trend for Sonoma Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Interest Expense Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-0.01

Sonoma Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sonoma Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Sonoma Pharmaceuticals (STU:O8Z) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sonoma Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was €-0.77 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was €0.04 Mil.

Sonoma Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

GuruFocus does not calculate Sonoma Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Sonoma Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Sonoma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SNOA:USA

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Sonoma Pharmaceuticals Headlines

No Headlines